PMC2129G12

N/A

Report date: 2026/04/10 20:01:49

NME

Base Information

Drug NamePMC2129G12

Drug Alias NamemRNA-LNP(PMC2129G12)PMC2129G12-mRNA-LNPPMC2129G12

ClassificationCell and gene therapy > Gene therapy > mRNABiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate > Ab-tLNP

Mechanisms of ActionAnti-EpCAMAnti-CD3

TargetsEpithelial cell adhesion moleculeT cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesForevertech Biotechnologies Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesPeople'S Hospital Of Gansu

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A